Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial
Authors
- Claus Sværke (ORCID: https://orcid.org/0009-0003-8149-841X)
- Shigeyuki Tahara (ORCID: https://orcid.org/0000-0001-8429-2028)
- Fumio Otsuka (ORCID: https://orcid.org/0000-0001-7014-9095)
- Michael Højby Rasmussen (ORCID: https://orcid.org/0000-0002-2210-0366)
- Gudmundur Johannsson (ORCID: https://orcid.org/0000-0003-3484-8440)
- Takaaki Endo (ORCID: https://orcid.org/0009-0005-6146-6394)
Institutions
- Okayama University (JP)
- Novo Nordisk (Denmark) (DK)
- Sahlgrenska University Hospital (SE)
- Nippon Medical School (JP)
- University of Gothenburg (SE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.3389/fendo.2025.1534891
- Citations
- 1
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Novo Nordisk